Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH
Information source: AstraZeneca
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Essential Hypertension; Left Ventricular Hypertrophy
Sponsored by: AstraZeneca
Official(s) and/or principal investigator(s):
F. Sonntag, MD, Principal Investigator, Affiliation: Cardiologist, Henstedt-Ulzburg
Andrea Pahor, MD, Study Chair, Affiliation: MED Dep., AstraZeneca Germany
The CandLE study with at maximum daily dose of 32 mg candesartan or 16/12. 5 mg
candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions,
i. e. under routine medical care conditions, the impact of the antihypertensive therapy with
candesartan or candesartan/HCT on relevant medical parameters related to the left ventricular
hypertrophy (LVH) as well as the efficacy and tolerability of candesartan or candesartan/HCT
in subjects suffering from essential hypertension..
Official title: Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Essential Hypertension and a Concomitant Disease Left Ventricular Hypertrophy
Study design: Cohort, Prospective
Primary outcome: to estimate under naturalistic conditions the impact of the antihypertensive therapy with candesartan or candesartan/HCT on pre-post change from Visit 1 to Visit 2 of Sokolow-Lyon index, Cornell index and Left Ventricular Mass Index.
to estimate the change of the systolic and diastolic blood pressure, separately by the (maximum) prescribed daily dose of candesartan or candesartan/ HCT
to gain further insight into the occurrence of unknown, unexpected and/or rarely occurring adverse events (AE) by estimating the incidence under naturalistic conditions.
Minimum age: N/A.
Maximum age: N/A.
- essential hypertension
- left ventricular hypertrophy
- under candesartan treatment
Locations and Contacts
Starting date: January 2007
Ending date: October 2007
Last updated: February 5, 2008